Press Releases
Archives
Public Relations Contacts
Font Size:
June 5, 2007
ABILIFY® (aripiprazole) Supplemental New Drug Application for Pediatric Patients with Schizophrenia Accepted for Priority Review by the U.S. Food and Drug Administration
May 23, 2007
Investigational Study Evaluates the Effectiveness of Aripiprazole in Adolescents with Schizophrenia
May 21, 2007
Six-Week Investigational Study in Adults with Major Depressive Disorder Evaluates the Effectiveness of Adjunctive Aripiprazole Therapy with Antidepressants
March 25, 2007
EVEREST Data on Short- and Long-Term Use of Otsuka’s Investigational Novel Treatment, Tolvaptan, Published in Journal of the American Medical Association and Featured in ACC’s Late Breaking Clinical Trials
January 23, 2007
Otsuka Pharmaceutical Co., Ltd. Announces Establishment of New Organization
November 16, 2006
New Data On Otsuka’s Investigational Product for Hyponatremia Presented at American Heart Association Annual Meeting
May 25, 2006
Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care in Management of Community-Treated Patients with Schizophrenia
May 25, 2005
New Investigational Data Using Intramuscular Administration of Aripiprazole in Patients with Acute Bipolar Mania and Schizophrenia
May 18, 2005
Multiple Studies at DDW Report on Adacolumn
®
Apheresis Device in Treating Inflammatory Bowel Disease
November 9, 2004
Poster on Investigational Otsuka Product Receives Presidential Poster Award from American College of Gastroenterology
May 18, 2004
Data Presented at Digestive Disease Week on Two Otsuka Products In Development for Inflammatory Bowel Disease
April 15, 2004
Dr. Ralph Harkins Joins Otsuka Maryland Research Institute, Inc. as Vice President, Biometrics
November 10, 2003
Otsuka's Tolvaptan Decreased Fluid Retention in Hospitalized Patients with Worsening Congestive Heart Failure
September 2, 2003
MR. Yoichi Nishinakamura Joins Otsuka Maryland Research Institute, Inc. as Chairman and Chief Executive Officer
July 22, 2003
Otsuka Initiates Phase III Clinical Trials on Compound for Ulcerative Colitis
October 31, 2002
'Control valve' within heart cells could protect body during heart attacks.
* OAPI, OPDC, and OMML are subsidiaries of Otsuka America, Inc. (OAI), a holding company established by OPC in the U.S. in 1989